Literature DB >> 16820797

Survival predictability of time-varying indicators of bone disease in maintenance hemodialysis patients.

K Kalantar-Zadeh1, N Kuwae, D L Regidor, C P Kovesdy, R D Kilpatrick, C S Shinaberger, C J McAllister, M J Budoff, I B Salusky, J D Kopple.   

Abstract

Although renal osteodystrophy and vitamin D analogs may be related to survival in maintenance hemodialysis (MHD) patients, most studies have examined associations between baseline values and survival without accounting for variations in clinical and laboratory measures over time. We examined associations between survival and quarterly laboratory values and administered paricalcitol in a 2-year (July 2001-June 2003) cohort of 58,058 MHD patients from all DaVita dialysis clinics in USA using both time-dependent Cox models with repeated measures and fixed-covariate Cox models with only baseline values. Whereas hypercalcemia and hyperphosphatemia were robust predictors of higher death risk in all models, the association between serum calcium and mortality was different in time-varying models. Changes in baseline calcium and phosphorus values beyond the Kidney Disease Outcome Quality Initiative recommended targets were associated with increased mortality. Associations between high serum parathyroid hormone and increased death risk were masked by case-mix characteristics of MHD patients. Time-varying serum alkaline phosphatase had an incremental association with mortality. Administration of any dose of paricalcitol was associated with improved survival in time-varying models. Controlling for nutritional markers may introduce overadjustment bias owing to their strong collinearity with osteodystrophy surrogates. Whereas both time-dependent and fixed-covariate Cox models result in similar associations between osteodystrophy indicators and survival, subtle but potentially clinically relevant differences between the two models exist, probably because fixed models do not account for variations of osteodystrophy indices and changes in medication dose over time.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16820797     DOI: 10.1038/sj.ki.5001514

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  284 in total

1.  Survival with three-times weekly in-center nocturnal versus conventional hemodialysis.

Authors:  Eduardo Lacson; Jianglin Xu; Rita S Suri; Gihad Nesrallah; Robert Lindsay; Amit X Garg; Keith Lester; Norma Ofsthun; Michael Lazarus; Raymond M Hakim
Journal:  J Am Soc Nephrol       Date:  2012-02-23       Impact factor: 10.121

2.  Association of cumulatively low or high serum calcium levels with mortality in long-term hemodialysis patients.

Authors:  Jessica E Miller; Csaba P Kovesdy; Keith C Norris; Rajnish Mehrotra; Allen R Nissenson; Joel D Kopple; Kamyar Kalantar-Zadeh
Journal:  Am J Nephrol       Date:  2010-09-03       Impact factor: 3.754

Review 3.  Kidney bone disease and mortality in CKD: revisiting the role of vitamin D, calcimimetics, alkaline phosphatase, and minerals.

Authors:  Kamyar Kalantar-Zadeh; Anuja Shah; Uyen Duong; Rulin C Hechter; Ramanath Dukkipati; Csaba P Kovesdy
Journal:  Kidney Int Suppl       Date:  2010-08       Impact factor: 10.545

4.  Decreases in PTH in Japanese hemodialysis patients with secondary hyperparathyroidism: associations with changing practice patterns.

Authors:  Tadao Akizawa; Ryo Kido; Masafumi Fukagawa; Yoshihiro Onishi; Takuhiro Yamaguchi; Takeshi Hasegawa; Shunichi Fukuhara; Kiyoshi Kurokawa
Journal:  Clin J Am Soc Nephrol       Date:  2011-08-11       Impact factor: 8.237

5.  Outcomes associated with phosphorus binders in men with non-dialysis-dependent CKD.

Authors:  Csaba P Kovesdy; Olga Kuchmak; Jun Ling Lu; Kamyar Kalantar-Zadeh
Journal:  Am J Kidney Dis       Date:  2010-08-21       Impact factor: 8.860

6.  Effects of sevelamer and calcium-based phosphate binders on lipid and inflammatory markers in hemodialysis patients.

Authors:  Ronney Shantouf; Matthew J Budoff; Naser Ahmadi; Jima Tiano; Ferdinand Flores; Kamyar Kalantar-Zadeh
Journal:  Am J Nephrol       Date:  2007-11-09       Impact factor: 3.754

7.  Positive association of vigorous and moderate physical activity volumes with skeletal muscle mass but not bone density or metabolism markers in hemodialysis patients.

Authors:  Yoshiyuki Morishita; Kazuya Kubo; Atushi Miki; Kenichi Ishibashi; Eiji Kusano; Daisuke Nagata
Journal:  Int Urol Nephrol       Date:  2014-02-13       Impact factor: 2.370

8.  Changes in Markers of Mineral and Bone Disorders and Mortality in Incident Hemodialysis Patients.

Authors:  Melissa Soohoo; Mingliang Feng; Yoshitsugu Obi; Elani Streja; Connie M Rhee; Wei Ling Lau; Jialin Wang; Vanessa A Ravel; Steven Brunelli; Csaba P Kovesdy; Kamyar Kalantar-Zadeh
Journal:  Am J Nephrol       Date:  2016-03-08       Impact factor: 3.754

Review 9.  Calcimimetics or vitamin D analogs for suppressing parathyroid hormone in end-stage renal disease: time for a paradigm shift?

Authors:  James B Wetmore; L Darryl Quarles
Journal:  Nat Clin Pract Nephrol       Date:  2008-10-28

10.  Sevelamer for hyperphosphataemia in kidney failure: controversy and perspective.

Authors:  Mario Cozzolino; Maria Antonietta Rizzo; Andrea Stucchi; Daniele Cusi; Maurizio Gallieni
Journal:  Ther Adv Chronic Dis       Date:  2012-03       Impact factor: 5.091

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.